Evidence map›Paper›PMID 39989146›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2025

Universal Prophylactic Antitumor Vaccination Using Stem Cell Membrane-Coated Nanoparticles.

Nishta Krishnan, Jiarong Zhou, Animesh Mohapatra, Christian John Ventura, Yaou Duan, Junyong Lee, Jacob J Hoenig, Oliver Nizet, Weiwei Gao, Ronnie H Fang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Intelligent Programmable Membrane Nanosponge for Early Virus Blocking.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nishta KrishnanAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Jiarong ZhouAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Animesh MohapatraAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Christian John VenturaAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Yaou DuanAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Junyong LeeAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Jacob J HoenigAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Oliver NizetAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Weiwei GaoAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Ronnie H FangAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.
Liangfang ZhangAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, 92093, USA.ORCID https://orcid.org/0000-0003-0637-0654

Funding

Inflammation-targeted delivery of corticosteroids using genetically engineered cellular nanoparticlesR21AI175904 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FANG, RONNIE H · 2023 to 2024
$435k
Defense Threat Reduction Agency HDTRA1-21-1-0010National Institute of Allergy and Infectious Diseases R21AI175904NIAID NIH HHS R21 AI175904
6 · The paper itself

Abstract

Cancer vaccines are a promising immunotherapeutic modality that function by training the immune system to recognize and destroy malignant cells. As tumor-specific and tumor-associated antigens generally cannot be identified until after a tumor has already been established, these vaccines must be applied therapeutically when strong immunosuppressive mechanisms are already in place. Building upon previous work using cell membrane coating nanotechnology, the development of a broad-spectrum prophylactic cancer nanovaccine that consists of induced pluripotent stem cell (iPSC) membrane coated around an adjuvant-loaded nanoparticle core is shown. The resulting nanostructure is capable of presenting iPSC-derived oncofetal antigens, which are oftentimes re-expressed on cancer cells but lowly present on normal adult tissues. When administered in vivo, the iPSC membrane-coated nanoparticles are highly immunostimulatory and elicit strong antitumor immunity that can successfully inhibit the growth of multiple tumor types, including five different murine tumor models and in a bilaterial heterogeneous tumor model. Overall, this work demonstrates an effective approach for engineering iPSC-based nanovaccines that can be applied broadly to prevent cancer before it occurs.

Indexed as

Cancer VaccinesCell MembraneInduced Pluripotent Stem CellsNanoparticlesNeoplasmsAnimalsCell Line, TumorFemaleHumansMiceVaccinationCancer Vaccinescell membrane coatingcellular nanoparticleiPSConcofetal antigenprophylactic cancer vaccine

Identifiers

PMID39989146
PMCPMC11983251

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.